Related Experiment Video
Updated: Mar 30, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
15.2K
[Benefits and risks for primary prevention with statins in the elderly]
Jean-Philippe Joseph1, Mélanie Afonso1, Driss Berdaï2
1Université de Bordeaux, département de médecine générale, 146, rue Léo-Saignat, 33076 Bordeaux cedex, France.
Presse Medicale (Paris, France : 1983)
|November 21, 2015
Summary
For individuals 75 and older, statins in primary prevention show no proven benefit for all-cause mortality and may increase adverse effects. The benefit versus risk is not established in this age group.
Area of Science:
- Cardiology
- Geriatric Medicine
- Pharmacology
Context:
- Statins effectively reduce cardiovascular events and mortality in primary prevention for those under 75.
- Evidence for statin efficacy and safety in individuals aged 75 and older is limited.
Purpose:
- To evaluate the effectiveness and safety of statin therapy for primary prevention in patients aged 75 and older.
- To determine the benefit-risk ratio of statins in elderly individuals for cardiovascular event prevention.
Summary:
- Review of randomized trials and meta-analyses indicates no demonstrated impact of statins on all-cause mortality in individuals over 75.
- Observational studies show a potential decrease in cardiovascular mortality but no change in all-cause mortality, alongside increased adverse effects and drug interactions.
- The benefit of statins for primary prevention in the elderly is not clearly established due to lack of evidence and potential harms.
Impact:
- Findings suggest that the benefit-risk balance of statins for primary prevention is uncertain in the elderly population.
- The economic implications and impact on quality of life warrant further analysis regarding statin discontinuation in individuals 75 and older.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
01:26Atherosclerosis III: Management
582
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
582
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
324
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
324
01:15Drug Dosing: Geriatric Patients
347
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
347
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
317
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
317
01:26Coronary Artery Disease IV: Preventive Measures
839
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
839